# Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy

> **NCT01472510** · PHASE2 · COMPLETED · sponsor: **Vitreo-Retinal Associates, PC** · enrollment: 20 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01472510
- **Lead sponsor:** Vitreo-Retinal Associates, PC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-07
- **Final completion:** 2014-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01472510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01472510, "Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01472510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*